[BREAKING] As we published this Thursday morning, news broke that Valeant is now under federal investigation in Massachusetts and New York for its drug-pricing practices. VRX shares were down 11.5% at open. Stay tuned here.
Every once in a while, a single company combines virtually all of the market’s most toxic forces. Today I feel it’s my job to expose Valeant Pharmaceuticals International Inc. (NYSE: VRX). for such a company and for the bad investment it is. Here’s why.
1. It’s got a risky and predatory business model.
2. It’s leveraged up to the hilt, with $30 billion of debt on just $9 billion in revenue in the trailing 12 months.
3. It’s on the radar of politicians, which is trouble for shareholders.
And here’s the real problem…
4. It’s widely owned by investors like you. Even if you don’t realize it, you may own this stock in any of the seven exchange-traded funds (ETFs) that hold it as a component.
Already VRX stock dropped 25% in September. In a Super Crash, it’s going to be much worse. This stock is a yo-yo. It gained 6.48% yesterday, but the day before, it lost 4.21%.
And it’s really in trouble now.
Today let’s just focus on Valeant’s cynical and leveraged business model.
This is a $60 billion multinational pharmaceutical company with a portfolio of prescription drugs, including Kinerase and Wellbutrin, one of the most frequently prescribed antidepressants in the United States, and consumer products, mostly in the skin, eye, and oral care segments. Valeant’s revenue more than doubled from 2012 to 2014, jumping from $3.48 billion to $8.25 billion in just two years.
But look closely as how it did that…
VRX has achieved its status as one of the fastest-growing pharmaceutical companies in the world while taking advantage of every conceivable legal and tax loophole available. It has enriched its management and a small group of hedge funds while contributing to skyrocketing healthcare costs and leaving the bill for U.S. taxpayers and consumers to pay.
VRX is the poster child for putting profits before principle.
VRX buys other companies using enormous amounts of junk bonds, then fires most of their employees to cut costs, and then raises the prices of the drugs it acquires. It spends only 3% of sales on research and development of new drugs compared to 15% to 20% for other drug companies. Take a look at the image below (from Wikipedia) for a sense of what Valeant’s “growth” has really looked like. The company claims that it isn’t “good” at R&D, but that is just an excuse because it has decided that it is more lucrative to buy other companies’ drugs and then mark up their prices. One example is the diabetes drug Glumetza, which belongs to Salix Pharmaceuticals. Valeant acquired Salix this year and promptly raised the price of Glumetza from around $896 to $10,000. (Look for the Oct. 5 New York Times report on this.) And the company pays very low taxes because it is officially based in Canada though it operates from New Jersey.
In other words, VRX is a highly leveraged “serial acquirer” that buys other companies only to fire their workers and hike the prices of their drugs for consumers whose costs fall mostly on insurance companies and the U.S. government. This is the state of corporate finance and healthcare policy in America in the Age of Obama.
But it’s about to backfire…
Next time I’ll show you something even more insidious.
Follow us on Twitter @moneymorning.
Editor’s Note: Overvalued biotech stocks like Valeant will get hit the hardest in the upcoming “Super Crash” Michael’s predicted. His Sure Money readers are getting the updates they need to protect themselves and take profits as stocks dive lower. Click here to receive Sure Money yourself at no charge, and you’ll get his Super Crash report, too.
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.To get full access to all Money Morning content, click here.
Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.